Targeted & controlled bone healing
  • slidebg1
  • slidebg1
  • slidebg1
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
30 Apr 19
Kuros Biosciences to propose re-appointment of Chairman and Board Members at Annual General Meeting


12 Apr 19
Kuros Biosciences reports results for the full year 2018
Financial highlights CHF 19.0 million cash & cash equivalents, trade and other receivables as at December 31, 2018 . Net operating costs decreased to CHF 14.3 million  . Operational highlights First U.S. & European sales of MagnetOs . Commercial rollout in the U.S. and Europe on track . Preparation for Phase II clinical study of Fibrin-PTH in spine on track . Raised CHF 16.1 million to advance product pipeline and commercialization of MagnetOs . READ MORE


Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
30 Apr 19
Kuros Biosciences to propose re-appointment of Chairman and Board Members at Annual General Meeting


12 Apr 19
Kuros Biosciences reports results for the full year 2018
Financial highlights CHF 19.0 million cash & cash equivalents, trade and other receivables as at December 31, 2018 . Net operating costs decreased to CHF 14.3 million  . Operational highlights First U.S. & European sales of MagnetOs . Commercial rollout in the U.S. and Europe on track . Preparation for Phase II clinical study of Fibrin-PTH in spine on track . Raised CHF 16.1 million to advance product pipeline and commercialization of MagnetOs . READ MORE